For patients with advanced NSCLC mutations, epidermal growth factor receptor-tyrosine kinase inhibitors have become an efficient and cutting-edge treatment.[74] Although few patients with PSC receive EGFR inhibitors, it is worth noting that patients with PSC carrying EGFR gene mutations lack significant and lasting clinical responses to EGFR inhibitors.[75,76] There is controversy about the probability of EGFR mutations in PSC, which may be caused by the frequency of EGFR mutations in PSC patients of different races, genders, and tumor subtypes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.